Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s from Cassava Sciences.
The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer’s disease — a benefit that no other treatment for Alzheimer’s has ever shown.
Asked by STAT to examine the simufilam data, Alzheimer’ scientists not involved in Cassava’s study said the cognitive benefit claim was exaggerated and not supported by the design of the clinical trial.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.